sharecast

{{ storiesRelated.title }}

Full List Of Stories
31 Mar
sturgeon
Sturgeon says 'no rational reason' for UK to block second referendum

Scotland First Minister Nicola Sturgeon said there was "no rational reason" for the UK government to block a second Scottish independence referendum.

31 Mar
frances o grady at tuc congress 2013
UK union body warns Brexit repeal hands workers' rights to judges

The UK government's plans to transfer EU law into British statute after Brexit would hand power to change workers' rights to judges rather than parliament, the Trades Union Congress warned.

31 Mar
Night tube/underground, London
FTSE 250 movers: Investec plunges on South Africa woes; Shawbrook rejection pleases

The South African political crisis worked its way into the FTSE 250 on Friday as Investec shares led the fallers list, down a hefty 9%.

31 Mar
shard, london, skyscraper
FTSE 100 movers: South Africans feel the pain after Zuma sacks finance minister

South African stocks weighed heavily as the major fallers on the FTSE 100 after President Jacob Zuma sacked Finance Minister Pravin Gordhan.

31 Mar
Facebook
Tech firms, Rudd fail to mention encryption after meeting

Tech firms said they would develop ways to “identify and remove terrorist propaganda” but failed to mention any movement on how to deal with encrypted messages, after a meeting with UK Home Secretary Amber Rudd.

31 Mar
donald tusk
EU rejects parallel talks on Brexit, trade deal with UK

Parallel talks on Britain's exit from the European Union and creating a new trade deal "will not happen", EU President Donald Tusk said on Friday in a firm rejection of UK Prime Minister Theresa May's demands.

31 Mar
lady gaga superbowl
Electra completes £203m Audiotonix sale

Electra Private Equity said it has completed the sale of console and mixing desk maker Audiotonix to French buyout group Astorg for £203m.

31 Mar
astrazeneca
AstraZeneca in rights deal with TerSera on cancer treatment

AstraZeneca said it had completed an agreement with TerSera Therapeutics for the commercial rights to its cancer treatment Zoladex in the US and Canada.